---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Access and distribution"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Access and distribution. Topics: Risk Evaluation and Mitigation Strategy expected, modeled on the Spravato REMS; Prescriber and provider training; Administration at a certified treatment center with session monitoring; Monitoring staffing: one primary monitor and closed-circuit television, two healthcare providers in total; 6 further topics. 10 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Risk Evaluation and Mitigation Strategy expected, modeled on the Spravato REMS

> “For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations.”
> “REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Again, we will not go into much detail on the REMS, but what we can say is what we have said publicly in the past, that the FDA directed us to use the SPRAVATO REMS as a template, and that would be where we see the direction going.”
> “It is extremely resource-intensive and complex, and we have an entire group at Compass who will help facilitate all of this.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-2"></a>

### Prescriber and provider training

> “Based on our interactions with the FDA as we work towards finalizing our REMS, we expect there to be training content within the REMS that will take about one to two hours to review.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin.”
> “In all, five organizations were awarded the grant, expanded from the originally three recipients due to the overall quality of applicants”

Source: [COMPASS Pathways provider training grant release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-U-S--Grant-Program-Recipients-for-the-Development-of-Post-Approval-COMP360-Provider-Training/default.aspx)

<a id="topic-2.1.2.11-3"></a>

### Administration at a certified treatment center with session monitoring

> “Prescribed by an HCP licensed to prescribe medication to patients”
> “Dosing and monitoring to take place at a certified treatment center”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

### Monitoring staffing: one primary monitor and closed-circuit television, two healthcare providers in total

> “If you look at the now finalized guidance from FDA for the design of clinical trials in psychedelics, our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers.”
> “We are, as I mentioned earlier, still finalizing the REMS in discussion with FDA, but we would certainly anticipate that the final requirements will be no more stringent than what has been required so far in clinical trials.”
> “This happens to match the current staffing models that are used in the interventional psychiatry clinics delivering SPRAVATO today.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-5"></a>

### Treatment-center network: more than 8,500 interventional psychiatry centers

> “COMP360 expected to fit seamlessly within an established and expanding infrastructure of more than 8,500 treatment centers”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “>8,500 Spravato® treatment clinics in US”
> “www.spravatohcp.com/find-treatment-center – data pulled 07/31/2026”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Seven years ago, when SPRAVATO launched, this infrastructure did not exist.”
> “Today, there are more than 8,500 interventional psychiatry treatment centers in place across the U.S., and it continues to grow rapidly.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-6"></a>

### Distribution channels: specialty pharmacy and buy-and-bill, reimbursed through the pharmacy benefit

> “COMP360 expected to be available through specialty pharmacy and buy-and-bill”
> “drug reimbursed through pharmacy benefit.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “COMP360 will be available through both specialty pharmacy and buy-and-bill, with drug reimbursed through pharmacy benefit.”
> “Right now, we think and believe SPRAVATO buy-and-bill volume is somewhere in the 30%-40% range of volume.”
> “In terms of preference, just using that as a proxy, we don't believe that buy-and-bill will be huge for COMP360 out of the gate, but we expect it to ramp to something very similar to SPRAVATO, potentially even surpassing it.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-7"></a>

### Monitoring billed through CPT Category III codes for psychedelic drug monitoring

> “CPTIII codes specifically for psychedelics”
> “billed by the hour through medical benefit”
> “Coding and reimbursement for COMP360 have not yet been established and are subject to change from current thinking”
> “CPT III codes accepted, and language released by AMA for Psychedelic Drug Monitoring Services; published in the CPT Manual and effective on January 1, 2024”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Ultimately, we anticipate that taking 12-18 months.”
> “But in the interim, as I said, sites will be supported to understand how they can code in the short term, and we will have patient support programs in place to ensure that affordability is not a barrier to access in the early days of the launch.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.11-8"></a>

### Payer engagement, reimbursement assistance, and patient support

> “In addition, over the past quarter, our newly expanded team of medical science liaisons have continued to educate clinicians on TRD and COMP360, and our payer access team has been actively engaging with payers across regional and national accounts, as well as state-level plans.”
> “We will also have a dedicated team of specialists working directly with clinics to facilitate the logistics associated with reimbursement for both the drug and the monitoring time for COMP360 administration.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “At approval, our top priority is site and patient experience”
> “REMS certification”
> “Reimbursement assistance”
> “Patient support hub”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.11-9"></a>

### Current reimbursement status of psilocybin as a Schedule I substance

> “Notwithstanding any of the above, as Schedule I substances under the Controlled Substances Act, psilocybin and psilocin are currently deemed to have no accepted medical use and therapies that use psilocybin or psilocin are currently precluded from reimbursement in the United States.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.11-10"></a>

### Federal and state rescheduling as a precondition of prescribing and distribution

> “Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially marketed.”
> “Facilities that manufacture, distribute, import or export any controlled substance must register annually with the DEA.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “So, that timing also needs to happen before a product can actually be prescribed and administered.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
